Cresilon has announced the nationwide commercial launch of TRAUMAGEL, a plant-based hemostatic gel designed for rapid bleeding control.
The product, which received 510(k) clearance from the U.S. Food and Drug Administration (FDA), is indicated for temporary external use in controlling moderate to severe bleeding.
TRAUMAGEL is now available for emergency medical technicians (EMTs), paramedics, first responders, and trauma healthcare providers.
It is supplied in a sterile, prefilled 30 mL syringe, requires no preparation, and is designed for quick application and removal.
Prior to its national release, Cresilon introduced the gel through a targeted rollout with emergency medical services (EMS) agencies, fire departments, and trauma centers in cities including Boston, New Orleans, Denver, and Columbus, Ohio.
Before launching nationwide, Cresilon deployed TRAUMAGEL through select EMS providers, fire departments, and Level I trauma centers.
The gel was used in field settings for cases involving extremity injuries, head lacerations, and penetrating wounds.
Frank Tranfaglia, Trauma Program Manager at a Level I trauma center in Denver, said: “I’ve seen firsthand the unmatched performance of TRAUMAGEL.
It’s reliable, easy to use, and stops bleeding extremely fast, even in challenging cases like a ground-level fall patient with a head wound on blood thinners—TRAUMAGEL worked flawlessly and immediately.
We’re excited to continue and expand our relationship with Cresilon, bringing this life-saving innovation to even more patients.”
TRAUMAGEL is the first syringe-applied hemostatic gel cleared for moderate to severe bleeding control.
It utilizes Cresilon’s proprietary hydrogel technology, which combines plant polymers to form a mechanical barrier when applied to a wound.
Cresilon CEO and co-founder Joe Landolina, who invented the technology, said: “The ability to control severe bleeding in a matter of seconds can be the difference between life and death for a patient with traumatic bleeding.
Building on the FDA clearance and success of our strategic rollout, we are launching TRAUMAGEL nationwide and continuing to move forward in our mission to save lives.”
Existing hemostatic devices and gauze-based solutions may require preparation or be difficult to apply, particularly in cases of severe hemorrhage.
Cresilon’s gel is designed for immediate use, with no preparation required.
The prefilled syringe format allows application to various wound types and geometries.
TRAUMAGEL is now being manufactured at Cresilon’s Brooklyn, New York facility and is available for purchase nationwide.
Healthcare providers can request training sessions through Cresilon.
Cresilon has launched TRAUMAGEL across the United States following an initial rollout with EMS agencies, fire departments, and trauma centers.
The FDA-cleared plant-based hemostatic gel is designed to stop moderate to severe bleeding quickly and is supplied in a prefilled syringe for easy application.
TRAUMAGEL is now available for EMTs, paramedics, and healthcare providers nationwide.
